Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor in Valvular Heart Disease

• Conditions: Severe Aortic Stenosis or Severe Aortic Regurgitation

• Registration Number: NCT04571372
• Lead Sponsor: Yonsei University

Brief Summary

This study investigates the association between level of suPAR and valvular heart disease in patients who have severe aortic stenosis or severe aortic regurgitation using commercially available suPARnostic standard enzyme-linked immunosorbent assay (ViroGates, Denmark)

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-08-13
• Study Start: 2020-09-23
• Study First Submitted QC: 2020-09-24
• Study First Posted: 2020-10-01
• Status Verified: 2020-11
• Last Update Submitted: 2020-11-26
• Last Update Posted: 2020-11-30
• Primary Completion: 2023-08
• Study Completion: 2023-08

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 250

Inclusion Criteria

• Age ≥ 19 yrs
• Severe aortic stenosis or severe aortic regurgitation
• Agree to consent for self
• Can follow-up for the next 2 years

Exclusion Criteria

• Pre-existing acute kidney injury
• Pre-existing end stage kidney disease: estimated glomerular filtration rate (eGFR) ≤15 ml/min/1.73m2 or receiving renal replacement therapy
• On ECMO or IABP
• Life expectancy < 12 months
• Pregnancy

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Number of participants with adverse clinical outcomes	2 years after recruiting	Composite of all-cause death, cardiovascular mortality, and worsening of kidney function

Trial Locations

Locations (1)

Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine; 🇰🇷 Seoul, Korea, Republic of